The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: the phase 3 JAVELIN Gastric 100 trial.
 
Markus H. Moehler
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly/ImClone; Merck Serono; MSD Oncology; Roche/Genentech; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer
Travel, Accommodations, Expenses - Amgen; Bayer; Merck Serono; Nordic Bioscience; Roche
 
Julien Taïeb
Honoraria - Amgen; Celgene; Lilly; Merck Serono; Roche; Sanofi
Travel, Accommodations, Expenses - Amgen; Celgene; Merck Serono; Roche
 
Jayne S. Gurtler
Travel, Accommodations, Expenses - EMD Serono; Medivation
Other Relationship - The Oncologist, Editor
 
Huiling Xiong
Employment - EMD Serono
 
Jenny Zhang
No Relationships to Disclose
 
Jean-Marie Cuillerot
Employment - EMD Serono
 
Narikazu Boku
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck Serono; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)